Our research primarily assessed DCC-2036’s capacity to inhibit tyrosine kinases (TKs) that are frequently overexpressed or activated in CRC, such as SRC, RAF, VEGFR2, MET, and FGR [11, 17–20]. The gene discussed is FGR; the disease is colorectal carcinoma.